Skip to Main content Skip to Navigation
New interface
Journal articles

Critical reappraisal of remdesivir investigational trials in COVID-19

Abstract : During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03149257
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Monday, October 17, 2022 - 8:43:08 AM
Last modification on : Tuesday, October 18, 2022 - 3:04:47 AM

File

S2052297520300974.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

Citation

P. Brouqui, A. Giraud-Gatineau, D. Raoult. Critical reappraisal of remdesivir investigational trials in COVID-19. NEW MICROBES AND NEW INFECTIONS, 2020, 38, ⟨10.1016/j.nmni.2020.100745⟩. ⟨hal-03149257⟩

Share

Metrics

Record views

0

Files downloads

0